bluebird gene therapy - Search News

high-flying bluebird bio sells itself to private equity

Reuters on MSN · 1d

Gene therapy maker bluebird to go private in discounted deal amid cash crunch

Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle and SK Capital Partners at a discount, ending its tumultuous journey in the public markets as it struggled with a severe cash crunch.

Hosted on MSN · 23h

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

YAHOO!Finance · 1d

What's Going On With Gene Therapy Company Bluebird Bio Stock Today?

Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners. The agreement, which also includes a team of biotech executives,

BioPharma Dive1d

Bluebird, at risk of default, agrees to take-private deal

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

Once valued at $10B, bluebird bio sold to private equity firms for $29M

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

17h

Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Pharmalittle: We’re reading about RFK Jr. targeting CDC and FDA advisers, a Pfizer gene therapy, and more

HHS Secretary Robert F. Kennedy Jr. is preparing to remove committee members who advise the government on vaccine approvals ...

GlobalData on MSN1d

Pfizer shelves haemophilia gene therapy Beqvez amid low demand

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

4don MSN

High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results